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Abstract
Two key events, namely adhesion and invasion, are pivotal to the occurrence of metastasis. Importantly, the 37 kDa/67 kDa
laminin receptor (LRP/LR) has been implicated in enhancing these two events thus facilitating cancer progression. In the
current study, the role of LRP/LR in the adhesion and invasion of liver cancer (HUH-7) and leukaemia (K562) cells was
investigated. Flow cytometry revealed that the HUH-7 cells displayed significantly higher cell surface LRP/LR levels
compared to the poorly-invasive breast cancer (MCF-7) control cells, whilst the K562 cells displayed significantly lower cell
surface LRP/LR levels in comparison to the MCF-7 control cells. However, Western blotting and densitometric analysis
revealed that all three tumorigenic cell lines did not differ significantly with regards to total LRP/LR levels. Furthermore,
treatment of liver cancer cells with anti-LRP/LR specific antibody IgG1-iS18 (0.2 mg/ml) significantly reduced the adhesive
potential of cells to laminin-1 and the invasive potential of cells through the ECM-like Matrigel, whilst leukaemia cells
showed no significant differences in both instances. Additionally, Pearson’s correlation coefficients suggested direct
proportionality between cell surface LRP/LR levels and the adhesive and invasive potential of liver cancer and leukaemia
cells. These findings suggest the potential use of anti-LRP/LR specific antibody IgG1-iS18 as an alternative therapeutic tool
for metastatic liver cancer through impediment of the LRP/LR- laminin-1 interaction.
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Introduction
Cancer is a global burden that has been shown to be the leading
cause of death in economically developed countries and the second
leading cause of death in economically developing countries[1].
According to the World Cancer Research Fund (WCRF), an
estimated 14.1 million cases of cancer were diagnosed in the year
2012 and it is predicted that approximately 24 million new cases of
cancer will be diagnosed by the year 2035, globally (http://www.
wcrf.org/cancer_statistics/). Currently, lung cancer has been
identified as the most commonly diagnosed cancer type, with the
two cancer types central to the present study namely liver cancer
and leukaemia, being ranked as sixth and eleventh most diagnosed
cancer types, respectively (GLOBOCAN). It has been reported
that approximately 782000 cases of liver cancer and 352000 cases
of leukaemia were diagnosed in the year 2012 (http://www.wcrf.
org/cancer statistics/world cancer statistics.php), thus indicating
the pressing need to develop effective treatments against cancer.
Cells are largely dependent on the extracellular matrix (ECM),
which is the non-cellular component of all tissues and organs that
provides a physical scaffold to cellular components and also assists
with initiation of essential biochemical processes needed for proper
tissue differentiation, homeostasis and morphogenesis[2]. Cells
adhere to the ECM via the action of ECM receptors[2].
Particularly, the non-integrin 37-kDa/67-kDa laminin receptor
(LRP/LR) is a major component of the extracellular matrix,
assisting in numerous physiological processes[3,4,5]. It is suggested
that 37-kDa LRP is the precursor of the 67-kDa high affinity
laminin receptor LR, however, the exact mechanism by which the
precursor forms the receptor is unknown[6].
LRP/LR is predominantly a transmembrane receptor, howev-
er, it is also evident in the nucleus and the cytosol[7,8]. In the
nucleus, LRP/LR plays a critical role in the maintenance of
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nuclear structures whilst in the cytosol, it assists in translational
processes[8]. As a transmembrane receptor, LRP/LR serves
several functions such as cell migration[9], cell-matrix adhe-
sion[10], cell viability and proliferation[3,4,5].
LRP/LR has been shown to have a high binding affinity for
laminin-1. Laminin-1 is part of a family of laminins, which are
extracellular matrix proteins that constitute several non-collage-
nous glycoproteins that are found in the basement mem-
brane[11,12]. This glycoprotein is believed to play critical roles
in cell attachment[11], assembly of the basement membrane[11],
cell growth and differentiation[13], cell migration[11,14], neurite
outgrowth[11,15] and angiogenesis[16]. Laminin-1 has also been
shown to promote the invasive phenotype of tumorigenic cells[17].
LRP/LR has been found to be over-expressed on the surface of
several tumorigenic cells[18]. The result of this over-expression is
an increased interaction between LRP/LR and laminin-1, and this
interaction has been shown to be crucial in enhancing adhesion
and invasion – two key components of metastasis[19]. Essentially,
laminin-1 in the basement membrane interacts with LRP/LR on
the surface of tumorigenic cells leading to adhesion[19]. This, in
turn, results in the secretion of proteolytic enzymes such as type IV
collagenase in order to hydrolyse type IV collagen in the basement
membrane, thereby allowing tumorigenic cells to invade and
eventually translocate to a secondary site[19].
Since the LRP/LR-laminin-1 interaction has been identified as
the crucial event in adhesion and invasion, blockage of this
interaction could be deemed as an essential mechanism to treat
metastatic cancer. This implicates LRP/LR as a target for the
treatment of metastatic cancer. Furthermore, several studies have
shown that application of anti-LRP/LR specific antibodies
significantly reduces the adhesive and invasive potential of certain
tumorigenic cells, such as HT1080 fibrosarcoma[18], lung[4],
cervical[4], colon[4], prostate[4], breast[20] and oesophageal[20]
cancer cells. Particularly, anti-LRP/LR specific antibody IgG1-
iS18 has been suggested to interrupt the LRP/LR-laminin-1
interaction [4], thus IgG1-iS18 may be deemed as a possible
therapeutic tool in the treatment of metastatic cancer.
In this study, the ability of anti-LRP/LR-specific antibody
IgG1-iS18 to impede the adhesive and invasive potential of
leukaemia and liver cancer cells was investigated. Due to the high
incidence and mortality rates regarding these two cancer types,
alternative therapeutic options become a necessity. It is notewor-
thy that similar studies have been conducted, however, it is
possible that not all metastatic cancer cell types may be responsive
to IgG1-iS18 treatments. It therefore becomes necessary to carry
out these metastatic studies on different cancer types in order to
gain insight into the use of the antibody as an alternative broad
spectrum therapeutic antibody for the treatment of various cancer
types. Thus, this study was conducted with the aim of determining
whether IgG1-iS18 is capable of significantly reducing the
adhesive and invasive potential of leukaemia and liver cancer
cells, therefore providing the possibility for the antibody to be used
as an alternative therapeutic tool in the treatment of these two
cancer types.
Materials and Methods
Cell culture and conditions
Human breast adenocarcinoma (MCF-7), liver carcinoma
(HUH7) and leukaemia (K562) cell lines obtained from ATCC
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
high glucose (4.5 g/l) supplemented with 10% fetal calf serum and
1% penicillin/streptomycin at 5% CO2 and 37uC.
Reagents and antibodies
Matrigel used for cell invasion assays is derived from the
Engelbreth-Holm-Swarm (EHS) mouse sarcoma and was obtained
from BD Biosciences.
Laminin-1used for cell adhesion assays was obtained from
Sigma-Aldrich.
Chloramphenicol acetyl transferase (CAT) antibody was
obtained from Sigma-Aldrich.
IgG1-iS18 was recombinantly produced in a mammalian
expression system as reported by
Zuber et al., (2008)
Confocal microscopy
In order to visualize the location of LRP/LR on the cell surface,
confocal microscopy was employed. Cells were first seeded on
coverslips and allowed to reach 70% confluency. Cells were fixed
in 4% paraformaldehyde in PBS for approximately 15 minutes
followed by several washes with PBS. Cells were blocked in 0.5%
BSA in PBS for 5-10 minutes. After one PBS wash, excess PBS was
blotted off. Cover slips containing cells were placed on a glass slide
(with cells facing upwards) and this was followed by addition of
primary antibody IgG1-iS18 (1:100) diluted in 0.5% BSA. Post an
overnight incubation at 4uC, coverslips were rinsed thrice in PBS/
BSA. After addition of the FITC-coupled secondary antibody that
had been diluted in 0.5% BSA, incubation in the dark was allowed
for 1 hour. Followed by three washes as before, DAPI diluted in
PBS was then administered for 5–10 minutes to allow for staining
of the nucleus. Cells were finally washed once in PBS alone and
mounted onto a clean slide using GelMount (Sigma-Aldrich). A
period of 45 minutes was allocated to allow for setting to take
place.
Flow cytometry
Quantification of cell surface levels of LRP/LR was conducted
using flow cytometry. EDTA(5 mM) in PBS was used to facilitate
detachment of adherent cells which was followed by centrifugation
at 1200 rpm, 10 min. Cells were subsequently fixed by re-
suspending cells in PFA for 10 min at 4uC. Cells were again
centrifuged in 1X PBS which allowed for the preparation of five
cell suspensions, one to which no antibody was added (thus serving
as the unstained control), one to which anti-CAT antibody was
added (serving as an isotype control) and one to which anti-LRP/
LR specific antibody IgG1-iS18 was added. The remaining two
cell suspensions were incubated only in PBS in order to be used as
negative controls for the IgG1-iS18 and anti-CAT antibody. All
suspensions were incubated at room temperature for 1 hour.
Following three washing steps with 1X PBS, goat anti-human
phycoerythrin (PE)-coupled secondary antibody (Beckman Coul-
ter) was added to the cell suspension containing the IgG1-iS18
primary antibody as well as one of the suspensions that was
incubated in PBS only. The cell suspension that was incubated
with the anti-CAT antibody as well as the remaining cell
suspension that was incubated only in PBS, were both supple-
mented with a goat anti-rabbit allophycocyanin (APC)-coupled
secondary antibody followed by another 1 hour incubation period
of all cell suspensions. Furthermore, three post-incubation washes
were performed and cell suspensions were analysed using the BD
Accuri C6 flow cytometer. Experiments were performed in
triplicate and repeated at least three times.
SDS PAGE and Western blotting
Total LRP/LR levels were determined by the use of sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
IgG1-iS18 Impedes Liver Cancer
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To perform the SDS-PAGE, 10 mg of total protein was used.
Proteins that were separated according to size by SDS-PAGE were
then identified by application of specific antibodies in the process
of Western blotting. The proteins resolved on the polyacrylamide
gel were transferred onto a polyvinylidene fluoride (PVDF)
membrane using 1X transfer buffer (20% methanol in 192 mM
glycine and 25 mM Tris) for 45 minutes at 350 mV and a semi-
dry transferring apparatus. Blocking buffer (3% BSA in 1X PBS
Tween) was then used in order to block the blotted membrane for
1 hour. Once blocked, the membrane was probed with anti-LRP/
LR specific primary antibody IgG1-iS18 (1:10000) for 1 hour.
Prior to incubation of the membrane with goat-anti-human-
peroxidase (1:5000) secondary antibody, three washes with 1X
PBS Tween were performed. A further three washes in 1X PBS
Tween were performed after incubation in the secondary
antibody, followed by the detection of HRP by use of an
enhanced chemiluminescent substrate (Thermo scientific). The
resulting fluorescence was developed and fixed onto an X-ray film.
Experiments were executed in triplicate and repeated at least 3
times.
Adhesion assay
In order to assess the adhesive potential of the varying
tumorigenic cell lines to the basement membrane in vitro,
laminin-1 (10 mg/ml)(BD Biosciences) was used to coat 96
microwell plates, leaving uncoated wells to be used as negative
controls. After the coating of the wells for 1 hour and washing with
0.1% BSA in DMEM, other protein binding sites on the microwell
plate were blocked using 100 ml of 0.5% BSA in DMEM for one
hour. Cells were suspended in serum-free culture medium and
added to wells at a density of 46105 cells/ml in order to assess the
adhesion potential. Furthermore, cells that have been pre-
incubated with IgG1-iS18 (0.2 mg/ml) and with anti-CAT (Sigma,
0.2 mg/ml) antibody as the negative control were added to the
relevant wells in order to examine the effects of the antibodies on
the adhesion potential of the cells. The plates were incubated at
37uC for 1 hour and thereafter, non-adherent cells were washed
away with PBS and adherent cells were fixed with 4%
paraformaldehyde for 10 minutes. Adherent cells were stained
with 0.1% crystal violet. The stain was extracted using 1% SDS
and the absorbance of the extracted sample at 550 nm was assayed
as a measure of the adhesive potential. Experiments were
performed in triplicate and repeated at least three times.
Invasion assay
In vitro analysis of the ability of the tumorigenic cell lines to
invade the basement membrane was carried out using the ECM-
like Matrigel. Serum-free cold culture medium (DMEM) was used
in order to dilute the Matrigel and this diluted gel was dispensed
onto the upper chamber of a 24 transwell plate (BD falcon, 8 mm
pore size). This gel was then allowed to solidify for approximately
5 hours at 37uC. After being harvested, cells were resuspended in
serum-free culture media at a density of 16106 cells/ml. Antibody
treatments required cells to be incubated with IgG1-iS18 (0.2 mg/
ml) or the negative control anti-CAT (Sigma, 0.2 mg/ml) antibody.
Cells were subsequently loaded onto the upper Matrigel-covered
chamber and incubated for 18 hours. The lower chamber was
filled with 500 ml of culture media containing 10% FCS (for the
test) and no FCS (for the control), and incubated at 37uC for
18 hours. This was followed by aspiration of the media in the
lower and upper chamber. Non-invasive cells were then removed
by use of a cotton swab. The remaining invasive cells were then
washed with 300 ml of PBS and fixed using 300 ml of 4%
paraformaldehyde, 10 min. Cells were stained using 0.5%
toluidine blue dye and after extraction of the dye using 1%
SDS, absorbance was then measured at 620 nm using an ELISA
reader. Experiments were carried out in triplicate and repeated at
least three times.
Statistical evaluations
The two-tailed Student’s t-test with a confidence interval of
95% was used in order to analyse the data, with p-values of less
than 0.05 being considered significant. The extent or degree of
association between LRP/LR levels on the cell surface and
invasive/adhesive potential was measured using the Pearson’s
correlation coefficient. The Pearson’s correlation coefficient
was also used to measure the correlation between the adhesive
and invasive potential of the cell lines. A positive coefficient
was an indication of direct proportionality between the two
variables, whereas a negative coefficient implied inverse
proportionality.
Results
Liver cancer and leukaemia cells reveal LRP/LR on the cell
surface
Pivotal to the occurrence of metastasis is the interaction
between laminin-1 and LRP/LR on the cell surface. Hence, it
was necessary to visualize cell surface LRP/LR as a means of
confirmation that cells indeed do display LRP/LR on their
surface. Both tumorigenic cell lines, as well as the poorly-
invasive breast cancer control, revealed LRP/LR on the cell
surface as depicted in Fig.1 a). The green fluorescence in the
images below is indicative of cell surface LRP/LR as cells were
non-permeabilized and the secondary antibody was shown to
not bind non-specifically, as confirmed by the controls
depicted in Fig.1 b) and Fig.1 c) below. Anti-CAT antibody
was used as a negative control due to its ability to bind
specifically to chloramphenicol acetyltransferase (CAT) which
is a bacterial protein and is therefore absent in mammalian
cells.
High percentages of tumorigenic cells display LRP/LR on
the cell surface
Although confocal microscopy confirmed that the cell lines do
indeed display LRP/LR on their cell surface, further quantifica-
tion of the cell surface levels of LRP/LR was required. Flow
cytometry was employed for this quantification.
As shown in Fig.2 A, C and E, all three tumorigenic cell lines
revealed high percentages of cells within a specific population
that display LRP/LR on the cell surface, with the shift between
the two peaks in each graph being indicative of a change in
fluorescence intensity due to the cell-surface staining of the cells
with anti-LRP/LR specific antibody IgG1-iS18 and the fluoro-
chrome-coupled secondary antibody. HUH-7 liver cancer cells
displayed a higher percentage of cells exhibiting LRP/LR on the
cell surface in comparison to K562 leukaemia cells as well as the
poorly-invasive breast cancer (MCF-7) control cell line. Fig. 2 B,
D and F additionally include the unstained control and this
control served to show that the PE secondary antibody does not
bind non-specifically. The shifts in fluorescence intensity of
unstained, APC only and anti-CAT-APC labelled cells (the
negative controls) are represented in the Fig S1. It is also
noteworthy to add that cell debris and cell aggregates were
excluded from analysis as they were outside the defined gate (Fig.
S3).
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Liver cancer cells display significantly higher and
leukaemia cells display significantly lower cell surface
LRP/LR levels compared to poorly-invasive breast cancer
cells
In addition to the percentage of cells exhibiting LRP/LR on
their cell surface, the actual cell surface LRP/LR levels within a
specific cell population was analyzed using flow cytometry. The
same number of cells (20000 cells) within specific populations of
the three tumorigenic cell lines were labelled with the same
concentration (30 mg/ml) of previously-mentioned primary and
secondary antibodies over the same time period. Thus, the more
LRP/LR that is present on the surface of the tumorigenic cells, the
more primary antibody IgG1-iS18 would bind to LRP/LR and
subsequently, the more IgG-specifc fluorochrome-coupled second-
ary antibody would bind to the primary antibody. Thus, the
median fluorescence intensities (MFI) would differ between the
three cell lines (Table 1) and therefore can be used as an indicator
of cell surface LRP/LR levels. It was observed that, in comparison
to the poorly-invasive MCF-7 breast cancer control cell line, liver
cancer cells (HUH-7) displayed higher levels of LRP/LR on their
cell surface (Fig.3). Additionally, K562 leukaemia cells revealed
lower cell surface LRP/LR levels in comparison to the MCF-7
cells (Fig.3).
The median fluorescence intensities obtained post anti-CAT
labelling and detection demonstrate that there is no significant
difference in the degree of cell-surface CAT staining across all
three cell lines (Fig. S2)
Total LRP/LR levels do not differ significantly between
the tumorigenic cell lines
As previously mentioned, LRP/LR does not exclusively occur
on the cell surface but is additionally seen in the nucleus and
cytosol, hence Western blot analysis was performed in order to
assess total LRP/LR levels. Experiments were performed in
triplicate and repeated three times. A representative blot is
depicted in Fig.4. It is noteworthy to state that only the 37 kDa
laminin receptor precursor could be detected by use of anti-LRP/
LR specific antibody IgG1-iS18.
Following detection of LRP, quantification of total LRP levels
was required and densitometry was employed to achieve this. Fig.5
depicts the densitometric analysis, which revealed that statistically,
there was no significant difference observed in total LRP levels
between the three tumorigenic cell lines.
IgG1-iS18 significantly impedes the adhesive potential of
liver cancer cells
Pivotal to the initiation of invasion is the adhesion of a
tumorigenic cell to the basement membrane through the LRP/
LR-laminin-1 interaction as it allows for other interactions to
occur that facilitate degradation of the basement membrane. Cells
were incubated with IgG1-iS18 and anti-CAT antibodies (0.2 mg/
ml) and after an hour, absorbance readings of the resultant
solution were indicative of the degree of cell attachment to the
laminin-1-coated plates.
As depicted in Fig.6, the no antibody control allowed for the
determination of the adhesive potential of the cell lines and it
was observed that both liver cancer (HUH-7) as well as
leukaemia cells (K562) were more adherent than the poorly-
invasive breast cancer (MCF-7) control cells. However, IgG1-
iS18 was only effective at impeding the adhesive potential of
liver cancer cells and no significant reduction in adhesion was
observed for leukaemia cells treated with the anti-LRP/LR
specific antibody IgG1-iS18. As expected, the anti-CAT
Figure 1. Visualisation of LRP/LR on the surface of liver cancer (HUH-7) and leukaemia (K562) cells. Cells were non-permeabilized in
order to allow for visualisation of the cell surface. a) Cells were labelled with primary antibody IgG1-iS18 and a FITC-coupled secondary antibody. b)
Cells were labelled with anti-chloramphenicol acteyltranferase (CAT) antibody as the negative control. c) Cells were labelled only with the FITC-
coupled secondary antibody to confirm that the secondary antibody does not bind non-specifically.
doi:10.1371/journal.pone.0096268.g001
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control antibody did not have a significant effect on the
adhesive potential of the tumorigenic cell lines.
Invasion of the Matrigel by liver cancer cells (HUH-7) is
significantly impeded by anti-LRP/LR specific antibody
IgG1-iS18
Invasion of the basement membrane is considered as a pre-
requisite for the progression of a metastatic cancer, hence invasion
assays using a Matrigel, which mimics the components of the
basement membrane, were performed to determine the invasive
potential of the tumorigenic cell lines. Similarly to the adhesion
assays, the no antibody control allowed for the determination of
the invasive potential of the cell lines. Furthermore, cells were
treated with anti-LRP/LR specific antibody IgG1-iS18 and anti-
CAT antibody (0.2 mg/ml).
As shown in Fig.7, liver cancer (HUH-7) cells are significantly
more invasive in comparison to the poorly-invasive breast cancer
(MCF-7) control cell line, whilst leukaemia (K562) cells showed a
significantly lower invasive potential compared to the control.
Moreover, IgG1-iS18 successfully hampered the invasive potential
of liver cancer (HUH-7) cells whilst no significant result was
observed for the leukaemia cells. As expected, the anti-CAT
antibody control did not significantly affect the invasive potential
of the tumorigenic cell lines.
Discussion
Several studies have revealed that, on the cell surface, various
tumorigenic cell lines exhibit an overexpression of the 37 kDa/
67 kDa LRP/LR, therefore suggesting that the LRP/LR-laminin-
1 interaction may be pivotal for cancer cells to undergo
metastasis[21]. It may therefore be useful to inhibit this interaction
as a means of hampering adhesion and invasion – two events
found to be crucial to the occurrence of the process of metastasis.
A study conducted by Zuber et al has demonstrated that the IgG1-
iS18 antibody is highly specific for LRP/LR[18]. Furthermore,
recent research has shown that anti-LRP/LR specific antibody
IgG1-iS18 significantly impedes the adhesive and invasive
potential of cervical[4], lung[4], prostate[4], colon[4], breast[20]
and oesophageal[20] cancer cells. The present study investigated
the role of LRP/LR in the adhesion and invasion of liver cancer
(HUH-7) as well as leukaemia (K562) cells, and aimed to establish
whether application of anti-LRP/LR specific antibody IgG1-iS18
significantly reduces the adhesive and invasive potential of these
two tumorigenic cell lines.
Initially, confocal microscopy revealed that all three tumori-
genic cell lines indeed display LRP/LR on their cell surface
(Fig. 1a). However, this technique is limited by the fact that it is not
quantitative and further analysis was required in order to establish
Figure 2. Quantification of liver cancer (HUH-7) and leukaemia (K562) cells within a population which exhibit LRP/LR on their cell
surface. The first peak in graphs A, C and E is representative of non-labelled cells i.e. cells labelled with goat anti-human PE-coupled secondary
antibody only, whereas the second peak is indicative of cells labelled with both anti-LRP/LR specific antibody IgG1-iS18 and the secondary antibody,
both at a concentration of 30 mg/ml. Graphs B, D and F depict the inclusion of an unstained control to show no non-specific secondary antibody
binding. Experiments were carried out in triplicate and repeated at least three times with 20 000 cells being counted per sample.
doi:10.1371/journal.pone.0096268.g002
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the levels at which LRP/LR is displayed on the cell surface of
these tumorigenic cell lines.
Significantly high percentages (.87%) of all three tumorigenic
cell lines, namely HUH-7, K562, and MCF-7 (poorly-invasive
breast cancer control) cells displayed LRP/LR on their cell surface
(Fig.2). Furthermore, it was observed by analysis of differences in
median fluorescence intensities that, in comparison to the MCF-7
control cell line, liver cancer cells (HUH-7) revealed significantly
higher and leukaemia cells (K562) revealed significantly lower cell
surface LRP/LR levels (Fig.3). As previously stated, LRP/LR
plays essential roles in adhesion, invasion, proliferation and
migration of cells[9]. Seeing that the HUH-7 cell line is known
to be invasive and the K562 is understood to be a suspension cell
line (ATCC), the cell surface levels of LRP/LR that have been
observed may be correlating with the invasive potential of these
cell lines.
Additionally, total LRP/LR levels were analysed by Western
blotting in order to account for LRP/LR in the nucleus and
cytosol of the tumorigenic cell lines. Western blot analysis (Fig.4)
confirmed that all three tumorigenic cell lines express the 37 kDa
LRP, however densitometry analysis of these blots (Fig.5) revealed
that both the invasive and poorly-invasive cell lines show similar
levels of total LRP and no significant differences were observed. It
is noteworthy to state that in the nucleus and cytosol, LRP/LR
serves particularly to maintain nuclear structures and facilitate
translational processes, respectively[8]. Hence, even though total
LRP levels do not differ significantly between the invasive and
poorly-invasive tumorigenic cell lines, the cell surface LRP/LR
levels are of importance to the occurrence of adhesion and
invasion in the invasive and poorly-invasive tumorigenic cell lines.
The current study revealed differences in only cell surface levels of
LRP/LR between the three tumorigenic cell lines, and this is in
agreement with results obtained in previously published research
[4]. However, another study contradicted these results by showing
that tumorigenic cell lines differed only in total LRP/LR
levels[20]. These discrepancies in the latter-mentioned study
could be owing to the fact that those cancerous cells may require
enhanced protein synthesis in order to carry out metastatic
processes, hence increased total LRP/LR levels were observed
rather than increased cell surface LRP/LR levels.
The results obtained in the present study suggests that anti-
LRP/LR specific antibody IgG1-iS18 caused a significant
reduction in the adhesive potential of metastatic liver cancer cells
on laminin-1 and additionally hampered the invasive potential of
Figure 3. Quantification of cell surface LRP/LR levels on liver cancer (HUH-7) and leukaemia (K562) cells by flow cytometry. Cells
were labelled with primary antibody IgG1-iS18 (1:25) and anti-human phycoerythrin (PE) secondary antibody. 20000 cells were analyzed across all
three cell lines, and the median fluorescence intensities (MFI) were used as an indicator of cell surface LRP/LR levels. The MFI values indicated in the
last column of Table 1 were used in order to construct this figure and it is noteworthy that the MFI value corresponding to the MCF-7 cell line was set
to 100%. Experiments were performed in triplicate and repeated at least three times. **p = 0.0025, ***p,0.0001.
doi:10.1371/journal.pone.0096268.g003
Table 1.Median fluorescence intensity (MFI) values as an indicator of differential expression of LRP/LR between MCF-7, HUH-7 and
K562 cell lines.
Cell lines MFI of unstained cells
MFI of cells labelled with
IgG1-iS18 and PE
(MFI of cells labelled with IgG1-iS18
and PE) – (MFI of unstained cells)
MCF-7 1623.666667 38753.16667 37129.5
HUH-7 2678.166667 49556 46877.83333
K562 13823.75 35392 21568.25
*All values are representative of an average of results obtained from experiments that were performed in triplicate and repeated three times.
doi:10.1371/journal.pone.0096268.t001
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this cancer type on the Matrigel. Figures 6 and 7 depict these
significant decreases in the adhesive and invasive potential of
metastatic liver cancer (HUH-7) cells upon administration of
IgG1-iS18, respectively. It is noteworthy to state that leukaemia
(K562) cells showed no significant reduction in the adhesive and
invasive potential upon administration of IgG1-iS18. It may be
suggested that variations in the adhesive and invasive potential of
both HUH-7 and K562 cell lines may be attributed to variations in
cell surface LRP/LR levels. Hence, lower cell surface LRP/LR
levels observed for leukaemia cells (Fig.3) could be held
accountable for the lower adhesive and invasive capacity observed
in this cell line, and vice versa for HUH-7 cells which exhibited
high cell surface LRP/LR levels (Fig.3) and resulted in the
increased adhesive and invasive capacity of this cell line. The
significant reduction in the invasive potential of metastatic liver
cancer cells after administration of anti-LRP/LR specific antibody
IgG1-iS18 may be attributed to the inhibition of adhesion (Fig.6)
by the IgG1-iS18 antibody, as adhesion is understood to be a pre-
requisite for the occurrence of invasion during the induction of
metastasis[20].
On the contrary, the K562 leukaemia cells were observed to be
more adherent (Fig.6) but less invasive (Fig.7) than the poorly-
invasive MCF-7 control cell line. This observation could be due to
K562 cells expressing tissue inhibitors of metalloproteinases
(TIMPs) and these TIMPs could be resulting in the inhibition of
type IV collagenase activity[22], thereby preventing degradation
of type IV collagen in the Matrigel and preventing K562 cells from
undergoing invasion in vitro.
Analysis of the correlation between cell surface levels of LRP/
LR with the adhesive and invasive potential of liver cancer (HUH-
7) and leukaemia (K562) cells, resulted in considerably high
correlation coefficients (Table 2). This signifies a positive and
directly proportional relationship between the two parameters.
Hence, this confirms that adhesion is a pre-requisite for invasion to
occur, as seen by the high correlation coefficients obtained for
adhesive to invasive potential for both experimental cell lines.
Furthermore, the high correlation coefficients obtained for cell
surface LRP/LR levels to the adhesive and invasive potential of
the cell lines suggests that the aggressiveness of these two cancer
types is enhanced by high levels of cell surface LRP/LR, which is
consistent with results obtained by previous studies [4,20]. It is
important to note that only cell surface levels of LRP/LR were
considered in the calculations of Pearson’s correlation coefficients
since no significant difference was observed in total LRP/LR levels
between the three tumorigenic cell lines (Fig.5).
In Table 2, the high Pearson’s correlation coefficients observed
between the adhesive and invasive potential for both cell lines
ascertains that adhesion is indeed a mandatory step for the
occurrence of invasion, where lower adhesive potential in
leukaemia cells subsequently resulted in a lower invasive potential
as well. This finding is in line with that of previously published
literature which shows that the LRP/LR-laminin-1 interaction is
pivotal for adhesion as well as secretion of enzymes that degrade
Figure 4. Detection of the relative expression of total 37 kDa
LRP levels using lysates of liver cancer (HUH-7) and leukaemia
(K562) cell lines. Anti-LRP/LR specific antibody IgG1-iS18 was used as
the primary antibody in conjunction with a secondary HRP-coupled
antibody. b-actin was employed as a loading control.
doi:10.1371/journal.pone.0096268.g004
Figure 5. Total LRP levels of liver cancer (HUH-7) and leukaemia (K562) cell lines detected by Western blot analysis using primary
anti-LRP/LR specific antibody IgG1-iS18 and goat anti-human HRP secondary antibody. Quantification was conducted using
densitometry and data are representative of experiments carried out in triplicate and repeated three times. Non-significant (NS): p.0.05.
doi:10.1371/journal.pone.0096268.g005
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Figure 6. Effect of anti-LRP/LR specific antibody IgG1-iS18 on the adhesion of liver cancer (HUH-7) and leukaemia (K562) cells to
laminin-1 determined through adhesion assays. p-values shown in red (*p = 0.0238; ***p= 0.0002) are indicative of the increase in adhesive
potential of liver cancer (HUH-7) and leukaemia (K562) cells in comparison to the breast cancer (MCF-7) control cell line. p-values shown in black
(**p = 0.0031; ***p = 0.0005) represent the reduction in adhesive potential after treatment of cells with appropriate antibodies. A reduction of 63.35%
in the adhesive potential was observed upon administration of IgG1-iS18 to the HUH-7 liver cancer cells. Data represents experiments performed in
triplicate and repeated at least three times.
doi:10.1371/journal.pone.0096268.g006
Figure 7. Effect of anti-LRP/LR specific antibody IgG1-iS18 on the invasion through the ECM-like MatrigelTM by liver cancer (HUH-7)
and leukaemia (K562) cells. p-values indicated in red (*p= 0.0485; **p = 0.0053) represent the changes in invasive potential of cell lines in
comparison to the MCF-7 control, whilst p-values shown in black (*p = 0.0214; **p = 0.0091) are indicative of the effect of appropriate antibodies on
the invasive potential of the cell lines. Upon administration of IgG1-iS18 to the HUH-7 liver cancer cells, a reduction of approximately 39.75% was
observed regarding the invasive potential of the cells. Data is representative of experiments carried out in triplicate and repeated at least three times.
doi:10.1371/journal.pone.0096268.g007
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the basement membrane and therefore promote invasion through
the basement membrane[23].
Several studies have suggested that anti-LRP/LR tools such as
pentosan sulphates and monoclonal antibodies directed towards
the laminin receptor have shown the potential to significantly
impede the adhesive and invasive potential of selected cancers
such as laryngeal carcinoma cells as well as human fibrosarcoma
cells through the interruption of the LRP/LR-laminin-1 interac-
tion [18,24].
Overall, it is strongly suggested that proteolytic cleavage of the
basal lamina and subsequently the process of invasion is
significantly enhanced through the LRP/LR-laminin-1 interac-
tion[23]. Furthermore, anti-LRP/LR specific antibody IgG1-iS18
has been shown in the present study to significantly impact on the
behaviour of metastatic liver cancer cells at the critical stages of
adhesion and invasion in vitro, thereby suggesting the use of the
antibody as an alternative therapeutic tool in the treatment of
metastatic liver cancer.
Due to different cancer types exhibiting different behavioural
characteristics, it cannot be assumed that anti-LRP/LR specific
antibody IgG1-iS18 will have the same effect on all cancer types.
Hence, the results of the current study will assist in providing the
scientific community with novel aspects regarding the use of the
antibody as a possible therapeutic tool for metastatic liver cancer.
Furthermore, studies concerning appropriate delivery systems for
the IgG1-iS18 antibody need to be conducted since LRP/LR
plays critical roles in several essential physiological processes and
the targeting of LRP/LR specifically in tumorigenic cells may
prove to be difficult. Successful animal trials may indeed deem the
antibody as a potential therapeutic tool for metastatic cancers.
Supporting Information
Figure S1 Quantification of liver cancer (HUH-7) and
leukaemia (K562) cells within a population which
display the CAT protein on their cell surface. The first
peak in graphs A,C and E represents cells labelled with APC-
coupled secondary antibody only, whilst the second peak indicates
cells that are labelled with both anti-CAT antibody as well as the
secondary antibody. The unstained control is included in graphs
B, D and F to confirm that the secondary antibody does not
significantly bind non-specifically. Experiments were performed in
triplicate and repeated at least three times with 20000 cells
counted per sample.
(TIF)
Figure S2 Quantification of cell surface CAT protein
levels on liver cancer (HUH-7) and leukaemia (K562)
cells by flow cytometric analysis. Cells were labelled with
anti-CAT antibody and APC-coupled secondary antibody. An
analysis was performed on 20000 cells per sample across all three
cell lines. The median fluorescence intensities of the samples
labelled with both anti-CAT antibody and the secondary antibody
were used as an indicator of CAT expression on the cell surface
(with the unstained control being taken into account). The MFI
value for the MCF-7 cell line wasset to 100%. Experiments were
carried out in triplicate and repeated at least three times. N.S: p.
0.05.
(TIF)
Figure S3 Flow cytometric gating of MCF-7 (poorly-
invasive breast cancer), HUH-7 (liver cancer) and K562
(leukaemia) cell samples. Cells were gated to exclude debris
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